| Literature DB >> 26473094 |
Mohsen Tabasi1, Mohammad Reza Asadi Karam1, Mehri Habibi1, Mir Saeed Yekaninejad2, Saeid Bouzari1.
Abstract
OBJECTIVES: Urinary tract infection caused by uropathogenic Escherichia coli (UPEC) strains is one of the most important infections in the world. UPEC encode widespread virulence factors closely related with pathogenesis of the bacteria. The purpose of this study was to evaluate the presence of different phenotypic virulence markers in UPEC isolates and determine their correlation with antibiotic resistance pattern.Entities:
Keywords: antibiotic resistance; patients' profiles; phenotypic virulence traits; urinary tract infection; uropathogenic Escherichia coli
Year: 2015 PMID: 26473094 PMCID: PMC4588432 DOI: 10.1016/j.phrp.2015.08.002
Source DB: PubMed Journal: Osong Public Health Res Perspect ISSN: 2210-9099
Prevalence of urinary tract infection in relation to significant patients' profiles.
| Patients' profiles | % Urinary tract infection | |
|---|---|---|
| Socioeconomic status | Well | 23.7 |
| < Intermediate | 76.3 | |
| Educational level | High | 19.9 |
| < Intermediate | 80.1 | |
| Patient status | Outpatient (community acquired UTI) | 34.6 |
| Inpatient (hospital acquired UTI) | 65.4 | |
| Treatment course | Complete | 53.8 |
| Incomplete | 46.2 | |
| Past history of recurrent | Present | 31.4 |
| Absent | 68.6 | |
| Sexual activity | Active | 74.4 |
| Not active | 25.6 | |
| Clinical diagnosis | Acute cystitis | 66 |
| Acute pyelonephritis | 14.1 | |
| Asymptomatic bacteriuria | 19.9 | |
UTI = urinary tract infection.
Figure 1Antimicrobial resistance pattern of UPEC isolates from patients with urinary tract infections (UTI). UPEC = uropathogenic Escherichia coli.
Antibiotic resistance profile among the urinary tract infection (UTI) patients with different clinical symptoms.
| Antibiotics | Acute cystitis | Acute pyelonephritis | ABU | |
|---|---|---|---|---|
| AMO | 68.9 | 50 | 32.2 | NS |
| TET | 66 | 63.6 | 38.7 | NS |
| NAL | 60.2 | 18.2 | 25.8 | 0.038* |
| PIP | 63.1 | 40.9 | 41.9 | NS |
| AMP | 86.5 | 59.1 | 61.3 | NS |
| CRO | 51.4 | 22.7 | 19.3 | 0.041* |
| CAZ | 40.8 | 50 | 9.7 | NS |
| CPM | 50.5 | 31.8 | 29 | NS |
| NOR | 58.2 | 54.5 | 35.5 | NS |
| COT | 71.8 | 45.4 | 22.6 | 0.029* |
* Significant at p < 0.05.
ABU = asymptomatic bacteriuria; AMO = amoxicillin; AMP = ampicillin; CAZ = ceftazidime; COT = cotrimoxazole; CPM = cefepime; CRO = ceftriaxone; NAL = nalidixic acid; NOR = norfloxacin; NS = not significant; PIP = piperacillin; TET = tetracycline; %R = percentage of resistance to antimicrobial agents.
Relationship between antimicrobial resistance and virulence factors of UPEC isolates.
| Virulence markers | Antimicrobial agents | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMO %R | TET %R | NAL %R | PIP %R | AMP %R | CRO %R | CAZ %R | CPM %R | NOR %R | COT %R | ||
| Biofilm formation | Strong | 82.1 | 67.8 | 17.8 | 71.4 | 96.4 | 64.3 | 60.7 | 67.8 | 75 | 85.7 |
| Moderate | 62 | 55.2 | 37.9 | 58.6 | 86.2 | 51.7 | 44.8 | 58.6 | 62.1 | 69 | |
| Weakly | 57.1 | 66.2 | 53.2 | 51.9 | 75.3 | 31.2 | 27.3 | 31.2 | 48 | 50.6 | |
| Negative | 31.8 | 36.4 | 77.3 | 45.4 | 50 | 31.8 | 22.7 | 36.4 | 31.8 | 36.4 | |
| NS | NS | 0.043* | NS | 0.042* | NS | NS | NS | 0.047* | 0.011* | ||
| Hemolysin production | Positive | 54.7 | 41.5 | 9.4 | 62.3 | 71.7 | 39.6 | 54.7 | 41.5 | 52.8 | 35.8 |
| Negative | 61.2 | 69.9 | 67 | 52.4 | 80.6 | 41.7 | 26.2 | 44.7 | 53.4 | 69.9 | |
| NS | 0.046* | 0.011* | NS | NS | NS | NS | NS | NS | 0.043* | ||
| HA type | MRHA | 53.4 | 50 | 60.3 | 34.5 | 67.2 | 43.1 | 32.1 | 55.2 | 46.5 | 43.1 |
| MSHA | 62.2 | 66.3 | 39.8 | 68.4 | 83.7 | 39.8 | 38.8 | 36.7 | 57.1 | 67.3 | |
| NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | ||
* Significant at p < 0.05.
AMO = amoxicillin; AMP = ampicillin; CAZ = ceftazidime; COT = cotrimoxazole; CPM = cefepime; CRO = ceftriaxone; HA = hemagglutination; MRHA = mannose resistant hemagglutination; MSHA = mannose sensitive hemagglutination; NAL = nalidixic acid; NOR = norfloxacin; NS = not significant; PIP = piperacillin; TET = tetracycline; UPEC = uropathogenic Escherichia coli; %R = percentage of resistance to antimicrobial agents.
Figure 2Comparison of antimicrobial resistance pattern among the ESBL and nonESBL producer UPEC isolates. * = significant. AMO = amoxicillin; AMP = ampicillin; CAZ = ceftazidime; COT = cotrimoxazole; CPM = cefepime; CRO = ceftriaxone; ESBL = extended spectrum beta lactamases; NAL = nalidixic acid; NOR = norfloxacin; PIP = piperacillin; TET = tetracycline; UPEC = uropathogenic Escherichia coli.
Distribution of virulence patterns of UPEC in relationship with clinical symptoms.
| Patterns | Phenotypic markers | No. of isolates | Clinical symptoms | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ESBL | Biofilm | Hemolysin | MRHA | MSHA | Acute cyctitis | Acute pyelonephritis | Asymptomatic bacteriuria | ||
| UP 1 | + | + | + | + | − | 9 | 3 | 6 | 0 |
| UP 2 | + | + | + | − | + | 13 | 7 | 4 | 2 |
| UP 3 | + | + | − | + | − | 5 | 4 | 0 | 1 |
| UP 4 | + | + | − | − | + | 9 | 7 | 0 | 2 |
| UP 5 | + | − | + | + | − | 1 | 0 | 1 | 0 |
| UP 6 | + | − | + | − | + | 1 | 1 | 0 | 0 |
| UP 7 | + | − | − | + | − | 2 | 1 | 0 | 1 |
| UP 8 | + | − | − | − | + | 2 | 0 | 0 | 2 |
| UP 9 | − | + | + | + | − | 6 | 2 | 3 | 1 |
| UP 10 | − | + | + | − | + | 14 | 8 | 3 | 3 |
| UP 11 | − | + | − | + | − | 31 | 22 | 2 | 7 |
| UP 12 | − | + | − | - | + | 46 | 37 | 1 | 8 |
| UP 13 | − | − | + | + | − | 3 | 1 | 2 | 0 |
| UP 14 | − | − | + | − | + | 6 | 6 | 0 | 0 |
| UP 15 | − | − | − | + | − | 1 | 0 | 0 | 1 |
| UP 16 | − | − | − | − | + | 7 | 4 | 0 | 3 |
ESBL = extended spectrum beta lactamases; MRHA = mannose resistant hemagglutination; MSHA = mannose sensitive hemagglutination; UP = UPEC pattern; UPEC = uropathogenic Escherichia coli.